anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A component for use in the production of artificial finger or toe nails or parts thereof comprises a hardenable viscous homogeneous solution substantially free of peroxide and consisting of polymethyl methacrylate, or a copolymer containing a major proportion of combined methyl methacrylate, in a polymerizable monomer, the solution containing a reducing agent, which, with a peroxide forms a Redox catalyst system in an amount of 0.5 to 1.0% by weight based on the amount of monomeric compound, and also a polymerization inhibitor, the component being of such a consistency as to be squeezable from a tube on to a part of a finger or toe which part can be primed with a liquid containing a peroxide, e.g. benzoyl peroxide, to form with the squeezed-on component a Redox catalyst system which causes the resultant applied component to harden.  The reducing agent may be a tertiary amine, e.g. dimethyl-p-toluidine, and the polymerization inhibitor may be hydroquinone, resorcinol or induline. The solution may also contain an additive which assists adhesion, e.g. polymers and copolymers of vinyl chloride, acrylate copolymers, copolymers of acrylic or methacrylic acid or their amides, copolymers of dienes.  Monomers specified are methyl methacrylate, glycol dimethacrylate and allyl methacrylate. The component or priming liquid may also include polyester resins and plasticizers, e.g. dibutyl phthalate and cellulose acetobutyrate.  Reference has been directed by the Comptroller to Specification 985,388.
PURPOSE: A skin care composition is provided to improve a skin organization, resolve a pimple, improve a skin color, and reduce pores by using a mixer of a tretinoin, a hydroquinone, and a dipotassium glycyrrhetinate. CONSTITUTION: A skin care composition, particularly liquid skin care composition which provide good skin cell renewal, reduction of comedones, improvement of skin color soothing action, skin smoothing and skin pore refinement. The skin care composition is made up of tretinoin, hydroquinone, and dipotassium glycyrrhetinate which are a reactive component. The skin care composition mixes the tretinoin, the hydroquinone, and the dipotassium glycyrrhetinate which are a reactive component in an alcoholic solution. The alcoholic base is an ethanol. The skin care composition is made up of desalt water of suitable amount of the tretinoin 0.005-0.05 % by weight, the hydroquinone 0.500-4.00 % by weight, and the dipotassium glycyrrhetinate 0.100-1.00 % by weight, the alcoholic base 35.00-55.00 % by weight, EDTA 0.010-0.05 % by weight, and the total amount of the mixer.
Patients will receive a protocol-based activity advice (one time) from the HF team (nurse, cardiologist and/or physiotherapist) that corresponds to the intervention group in terms of time and effort. Participants in the control group are encouraged to decrease their sedentary behaviour to the same extent as the intervention group, and if possible be physical active 30 minutes for 5 days a week.
The eligible patient will receive the drug Efalizumab, weekly for 12 weeks, by injection. The patient will be seen weekly for 12 weeks and every other week for the 12 weeks of follow up. At those visits, the patient can expect that a physical and skin exam will be done. At specific weeks, blood work will be drawn, clinical photography taken and a skin biopsy done. Two types of skin biopsies will be done after local anesthesia has been administered. One is a punch biopsy where a small piece of skin will be taken, the approximate size of a pencil eraser. The second type of skin biopsy is shave biopsy, where a postage sized piece of skin will be taken.
Chronic itch is a common and complex symptom often associated with skin diseases such as atopic dermatitis (AD). Although IL-27 is linked to AD, its role and clinical significance in itch remain undefined. We sought to investigate IL-27 function in itch using tissue-specific transgenic mice, various itch models, behavior scoring, RNA sequencing, and cytokine/kinase array. Our findings show that IL-27 receptors were overexpressed in human AD skin. Intradermal IL-27 injection failed to directly induce itch in mice but upregulated skin protease-activated receptor 2 (PAR2) transcripts, a key factor in itch and AD. IL-27 activated human keratinocytes, increasing PAR2 transcription and activity. Coinjection of SLIGRL (PAR2 agonist) and IL-27 in mice heightened PAR2-mediated itch. In addition, IL-27 boosted BST2 transcription in sensory neurons and keratinocytes. BST2 was upregulated in AD skin, and its injection in mice induced itch-like response. BST2 colocalized with sensory nerve branches in AD skin from both human and murine models. Sensory neurons released BST2, and mice with sensory neuron-specific BST2 knockout displayed reduced itch responses. Overall, this study provides evidence that skin IL-27/PAR2 and neuronal IL-27/BST2 axes are implicated in cutaneous inflammation and pruritus. The discovery of neuronal BST2 in pruritus shed light on BST2 in the itch cascade.
This study is designed to evaluate the safety, tolerability, and immunogenicity of the dose escalation of LK101. We used the traditional "3+3" dose escalation design, Subjects who have been pathologically diagnosed with advanced solid tumors and defined as failing all previous standard therapy. LK101 will be administered in a prime-boost schedule of 4 priming vaccination followed by 3 booster vaccinations. The dose escalation will be conducted in a sequential manner, enrolled patients were initially placed in cohort 1, in which the priming phase is administered at 2-week intervals. And then followed the next cohort 2, where the priming phase is administered at 1-week intervals. Decisions with regard to dose escalation to the next dose level will be made jointly by the investigators and the sponsor. AE data was collected until the 21 days following the last prime dose. safety and immunogenicity will also be used to inform the final dose and schedule. A minimum of 6 patients will be treated at the MTD/RP2D.
Odevixibat reduces serum bile acids in patients with PFIC and ALGS.

In Trial 1, a 24-week, randomized, double-blind, placebo-controlled trial conducted in 62 patients with a confirmed diagnosis of PFIC type 1 or type 2, the majority of patients (88.7%) had elevated serum bile acids above 100 mcmol/L at baseline [see Clinical Studies (14)]. Serum bile acids concentrations were reduced from baseline within 4-8 weeks of odevixibat treatment compared to placebo treatment. The decreased concentrations of serum bile acids fluctuated over time but generally were maintained during the treatment over 24 weeks. The extent of decrease in serum bile acids was similar between 40 and 120 mcg/kg.

Trial 3 is a 24-week, randomized, double-blind, placebo-controlled trial conducted in 52 patients with a confirmed diagnosis of ALGS who were administered treatment with BYLVAY 120 mcg/kg once daily [see Clinical Studies (14)]. At baseline, serum bile acids were variable ranging from 93 to 510 mcmol/L. Serum bile acid concentrations were reduced from baseline as early as Week 4 of odevixibat treatment and the reduction was generally maintained during treatment over 24 weeks.
PROBLEM TO BE SOLVED: To provide a file that keeps its cover surfaces less liable to swell in the vertical middle, is prevented from inclining and sticking out into an adjacent storage area, and is continuously stored in the center of a storage area even in a storage area on a transfer unit. SOLUTION: A file storage device carries files into and out of a file cabinet by means of a transfer unit. The files 6 have a boxlike shape and comprise holders 6a to 6c of different thicknesses. The thinnest holder 6a forms guide portions 9 by the upper and lower ends, and the other thicker holders 6b and 6c have at the upper and lower ends guide portions 9 of a width equal to the thickness of the thinnest holder 6a. The cabinet unit 1 has recessed guide grooves 8 having the substantially same width as the guide portions 9 of the holders 6 along the top and bottom of each shelf space. The files are stored in the file cabinet unit with their guide portions 9 at the upper and lower ends of the holders 6a to 6c fitted in the guide grooves 8 of the cabinet unit 1.
SMA is a neuromuscular disorder characterized by degeneration of spinal cord motor neurons and muscular atrophy. SMA is classified into three clinical subtypes according to the severity and age of onset (Types I, II and III). Type I SMA (also called severe, infantile or acute SMA, or Werdnig-Hoffman disease) is the most severe phenotype. The onset of symptoms is within the first 6 months of life, and weakness of intercostal muscles and lack of airway protection lead to respiratory insufficiency and aspiration pneumonia, often resulting in early infant death.

In our laboratory, our preliminary results indicate that HU treatment significantly increases both SMN mRNA expression and intact SMN protein levels in vitro. These data confirm previous observations that in vitro treatments of SMA lymphocytes with hydroxyurea resulted in augmentation of the SMN2 gene expression in a dose and time related manner. Based on these exciting pre-clinical data, coupled with the well-documented side-effect profile of HU in children, we are conducting a pilot clinical trial using HU in children with Type I SMA. This clinical trial study is intended to establish the safety profile in children with Type I SMA; to identify reliable outcome measures; and to detect the possible clinical efficacy of HU treatment in children with Type I SMA.
PROBLEM TO BE SOLVED: To expand the width of experiment selectivity performed within a prescribed time and to conscientiously reflect treatment on an organism with good reproducibility, by providing a supply means to supply at least one kind of treatment liquid to each beaker and a means to feed dried gas flow to each beaker. SOLUTION: A pad 40 is laid on the bottom part of each beaker 6 and a sample E on the pad 40. Water is fed through an inner cavity 31 to moisten the sample E, and then excess water is drained through a groove at a contracted part. Hair dye is injected through the inner cavity 31, the sample E is massaged, and rinsing water is injected through the inner cavity 31. After rinsing and squeezing the sample E, shampoo is measured and distributed through the inner cavity 31. The sample E is rinsed by feeding rinsing water through the inner cavity 31 after shampoo treatment. Then sample E is squeezed. The sample E is dried by air fed through the groove preferably by hot air.
Papillary thyroid carcinoma (PTC) is a common endocrine cancer with a good prognosis. Radioactive iodine is thought to be useful for individuals who have had a total or almost total thyroidectomy, but its effects are still controversial. The effects of radioactive iodine-131 (I-131) treatment on oxidative and chromosomal damage in PTC patients were examined in this study, which was carried out with 16 patients newly diagnosed with PTC and 20 healthy control subjects with similar age and gender. Blood samples were taken from patients with PTC at five sampling times (before total thyroidectomy, after total thyroidectomy, and seven days, six months, and one year after treatment) and from control subjects. The cytokinesis block micronucleus cytome (CBMN-cyt) assay parameters in peripheral blood lymphocytes of patients with PTC and controls were evaluated and plasma 8-hydroxydeoxyguanosine (8-OHdG) levels were measured. Furthermore, genome instability and oxidative DNA damage in peripheral blood lymphocytes and plasma of patients with PTC were evaluated before total thyroidectomy (n=16), after total thyroidectomy (before I-131 treatment) (n=16), seven days (n=10), six months (n=5), and one year after treatment (n=5). The numbers of CBMN-cyt assay parameters (micronucleus; MN and nucleoplasmic bridges; NPB) and 8-OHdG levels in patients with PTC were determined to be significantly higher than in those of the control subjects and these values significantly decreased after total thyroidectomy (before I-131 treatment). While the number of MN, apoptotic, and necrotic cells increased after I-131 treatment, it significantly decreased after six months and one year after treatment. The results achieved in this study suggest that I-131 treatment may pose a threat to cells and that radioactive iodine therapy should be avoided (if possible) for patients with PTC after total thyroidectomy.
Formulations and methods have been developed for delivering antigens to individuals in a manner that substantially reduces contact between the antigen and IgE receptors displayed on the surfaces of cells involved in mediating allergic responses, which target delivery of antigen to dendritic and other phagocytic APCs, and which have improved pharmacokinetics. By reducing direct and indirect association of antigens with antigen-specific IgE antibodies, the risk of an allergic reaction, possibly anaphylatic shock, is reduced or eliminated. Particularly preferred antigens are those that may elicit anaphylaxis in individuals, including food antigens, insect venom and rubber-related antigens. In the preferred embodiments, the compositions include one or more antigens in a delivery material such as a polymer, in the form of particles or a gel, or lipid vesicles or liposomes, any of which can be stabilized or targeted to enhance delivery. Preferably, the antigen is surrounded by the encapsulation material. Alternatively or additionally, the antigen is displayed on the surface of the encapsulation material. One result of encapsulating antigen is the reduction in association with antigen-specific IgE antibodies. In some embodiments, antigens are stabilized or protected from degradation until the antigen can be recognized and endocytized by APCs which are involved in elicting cellular and humoral immune responses. In a preferred embodiment, the formulation is designed to deliver antigens to individuals in a manner designed to promote a Th1-type mediated immune response and/or in a manner designed to suppress a Th2 response. In still another embodiment, the formulation effects preferential release of the antigen within APCs.
Subjects will lie supine on a treatment table and have their suboccipital region gently cupped by the therapist for 30 seconds. No movement or force will be applied, just simple manual contact.
Participants will receive the highest safe and well-tolerated dose identified in Part 1, infused over 1 hour. Randomization will be stratified according to severity at Baseline (mild versus moderate Alzheimer's Disease).
Chest CT imaging will be obtained in the radiology department at UTMB. After the initial screening visit, subjects will visit the pulmonary function laboratory where they will undergo spirometry and measurement of lung volumes by whole body plethysmography. Within two hours of pulmonary function testing, subjects will undergo an initial HRCT scan. After the initial HRCT, subjects will inhale a standard dose of ipratropium bromide (0.5 mg) using a hand held nebulizer. Thirty minutes after ipratropium bromide administration, spirometry will be measured followed by a second HRCT scan.

Spirometry measurements will be performed in triplicate with the subjects in a seated position using a portable Koko spirometer (PDS, Louisville, CO). After the spirometry measurements, lung volumes will be measured in a body plethysmograph (MedGraphics, St. Paul, MN) with the subjects in a seated position with a nose clip. Subjects will be instructed to pant against the closed shutter at a frequency of 1-3 Hz. Lung volume measurements will be obtained prior to inital chest CT. Subjects will undergo high resolution computed tomography (HRCT) scanning within 30 minutes of initial lung volume measurements.

After the initial HRCT of the chest, subjects will inhale a dose of nebulized ipratropium bromide (0.5 mg) by standard nebulizer after which spirometry and lung volume measurements will be repeated in the pulmonary function laboratory. Spirometry and lung volume measurements will be performed in the same manner. Lung volume measurements will be obtained to account for changes in lung volumes after bronchodilator administration. Changes in lung volumes will be used to account for any changes noted on HRCT scans.

HRCT scanning will begin 6 cm above the top of the dome of the diaphragm, at TLC and moved caudally. Images will be reconstructed with the use of a high-spatial frequency (resolution) algorithm that enhanced edge detection, at a window level of -450 Hounsfield units and a window width of 1,350 Hounsfield units. We will consider the airway diameters after maximum bronchodilation with ipratropium to be a function principally of the structural characteristics of airways. The TLC measurements after ipratropium will be the best reflection of intrinsic structure. CT airway measurement analysis will be performed by VIDA Diagnostics. We have entered into a collaboration with VIDA Diagnostics that will allow accurate and reliable CT airway measurements. Subject's CT images obtained at UTMB will be deidentified and electronically transmitted to a research collaborator at VIDA Diagnostics located in Coralville, IA. The CT images will have a code assigned, known only to the PI. Using a proprietary software platform, airway measurements will be performed and the data electronically transmitted to the PI at UTMB.
Isolated CDCA1-derived epitope peptides having Th1 cell inducibility are disclosed herein. Such peptides can be recognized by MHC class II molecules and induce Th1 cells. In preferred embodiments, such a peptide of the present invention can promiscuously bind to MHC class II molecules and induce CDCA1-specific cytotoxic T lymphocytes (CTLs) in addition to Th1 cells. Such peptides are thus suitable for use in enhancing immune response in a subject, and accordingly find use in cancer immunotherapy, in particular, as cancer vaccines. Also disclosed herein are polynucleotides that encode any of the aforementioned peptides, APCs and Th1 cells induced by such peptides and methods of induction associated therewith. Pharmaceutical compositions that comprise any of the aforementioned components as active ingredients find use in the treatment and/or prevention of cancers or tumors.
The invention discloses a Chinese herbal medicine rhizoma drynariae plaster and a preparation method thereof. The Chinese herbal medicine rhizoma drynariae plaster is prepared from 20-30 parts by weight of rhizoma drynariae, 15-25 parts by weight of raw monkshood, 20-30 parts by weight of frankincense, 15-30 parts by weight of clematis root, 15-30 parts by weight of whiteflower leadword root, 10-20 parts by weight of dahurian angelica root, 15-30 parts by weight of Vaseline, 10-20 parts by weight of tea oil and 2-5 parts by weight of menthol. Rhizome drynariae is warm in nature and has effects of moving qi and promoting blood circulation, and relaxing muscles and tendons. Raw monkshood has effects of dispelling wind and relieving pain. Frankincense has effects of dispelling wind and removing moisture. Clematis root has effects of softening spur. Whiteflower leadword root has effects of removing toxins and engendering flesh. Dahurian angelica root has effects of dispelling wind and stimulate the circulation of the blood. Menthol has effects of infiltrating medicine liquid into the skin and guiding the medicine into circulation of the blood. Through cooperation of the above materials, the Chinese herbal medicine rhizoma drynariae plaster has effects of dispelling wind and relieving pain, relaxing muscles and tendons and stimulating the circulation of the blood, softening bone, and removing toxins and engendering flesh. Long-term application observation proves that the Chinese herbal medicine rhizoma drynariae plaster has substantial effects on rheumatism ostalgia, cervical spondylosi, protrusion of lumbar intervertebral disc, arthritis and hyperosteogeny.
Atherosclerosis is a chronic inflammatory disease that affects arterial walls and is a leading cause of cardiovascular disease. Gene co-expression modules can provide insight into the molecular mechanisms underlying atherosclerosis progression. In this study, gene co-expression network analysis (WGCNA) was done to identify gene co-expression modules associated with atherosclerosis progression. Before conducting WGCNA, preprocessing and soft power selection were performed on the GSE28829, GSE100927, GSE43292, GSE10334, and GSE16134 datasets ( https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi ). Co-expression modules were identified using dynamic tree cuts, and their correlations and trait associations were visualized. Enrichment analysis was performed on the blue and magenta modules to identify biological processes (BP) and pathways related to atherosclerosis. The CIBERSORT algorithm was used to predict immune cell infiltration in early and advanced atherosclerotic plaques. We identified 12 co-expression modules, in which blue and magenta were most highly correlated with atherosclerosis progression. The blue module was enriched for inflammation- and immune-related BP and pathways, including phagosome, lysosome, osteoclast differentiation, chemokine signaling pathway, platelet activation, NF-kappa B signaling pathway, Fc gamma R-mediated phagocytosis, lipid and atherosclerosis, autophagy, and apoptosis. The magenta module was significantly enriched for vascular permeability regulation, positive and negative regulation of epithelial to mesenchymal transition, and lamellipodium. Additionally, the CIBERSORT algorithm predicted less abundance of T regulatory cells and monocytes in advanced compared to early atherosclerotic plaques. The enrichment analysis of BP, cellular components, molecular functions, and atherosclerosis-related pathways in the blue and magenta modules showed that inflammation and immune response played a key role in the progression of atherosclerosis. Our study provides insights into the molecular mechanisms underlying atherosclerosis progression and identifies potential therapeutic targets for the treatment of atherosclerosis. The identification of immune cell subtypes associated with atherosclerosis could lead to the development of immunomodulatory therapies to prevent or treat atherosclerosis.
In a tolerability study of intravenous dexmedetomidine in which healthy adult subjects were administered doses at and above the recommended dose of 0.2 to 0.7 mcg/kg/hour, the maximum blood concentration was approximately 13 times the upper boundary of the therapeutic range for the intravenous dexmedetomidine (IGALMI is not approved for intravenous use). The most notable effects observed in two subjects who achieved the highest doses were first degree atrioventricular block and second-degree heart block.

Five adult patients received an overdose of intravenous dexmedetomidine in intensive care unit sedation studies. Two patients who received a 2 mcg/kg loading dose (twice the recommended loading dose) over 10 minutes, experienced bradycardia and/or hypotension.

One patient who received a loading intravenous bolus dose of undiluted dexmedetomidine (19.4 mcg/kg), had cardiac arrest from which he was successfully resuscitated.

Consider contacting a Poison Center (1-800-222-1222) or a medical toxicologist for overdosage management recommendations for IGALMI.